Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
A single 3.6-mg Zoladex subcutaneous depot injection was effective in suppressing the pituitary-ovarian function for about 5 weeks in nine regularly menstruating, premenopausal volunteers. Menses returned approximately 9 weeks after the injection. Zoladex depot is a novel approach in the administration of GnRH agonists and offers great therapeutic potential.
D000328:Adult; D002064:Buserelin / Q000031:analogs & derivatives*; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008597:Menstrual Cycle / Q000187:drug effects; D011374:Progesterone / Q000097:blood*; D012016:Reference Values
D003692:Delayed-Action Preparations; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin